Protego Biopharma is a biotechnology company that develops therapeutics that aim to correct diseases caused by protein misfolding.
Protego Biopharma has raised $130.0M in total funding. The most recent round was Series B. The last funding was announced in December 2025.
Protego Biopharma's investors include Lightspeed Venture Partners, Digitalis Ventures, Omega Funds, Forbion Capital Partners, Vida Ventures.
Protego Biopharma is headquartered in San Diego, United States.
Protego Biopharma is a biotechnology company that develops therapeutics that aim to correct diseases caused by protein misfolding.
Protego Biopharma is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Protego Biopharma — Funding & Investors." VCBacked, December 1, 2025, https://www.vcbacked.co/company/protego-biopharma. Accessed August 1, 2026.
VCBacked. (2025). Protego Biopharma — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/protego-biopharma
{{cite web |title=Protego Biopharma — Funding & Investors |url=https://www.vcbacked.co/company/protego-biopharma |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated